Why Chronic GVHD Can Affect Mobility — and What You Can Do to Keep Moving

How GVHD Can Affect Movement
If you have chronic GVHD, here are some ways your mobility may be impacted.
Skin Tightening and Scarring
Thickened, hardened skin can restrict joint movement and make bending or stretching painful or difficult, says Christian Custodio, MD, a rehabilitation medicine specialist at Memorial Sloan Kettering Cancer Center in New York City. “Skin tightening is one of the more common manifestations,” he says.
Hardened, scarred skin can also prevent healing – for example, causing a simple abrasion like a blister to turn into an ulcer and limit mobility, explains Amin Alousi, MD, a hematologist-oncologist and the director of the graft-versus-host clinic and research program at MD Anderson Cancer Center in Houston. “This is a rare and severe complication of GVHD,” he says, but an important one to avoid to preserve movement.
Joint and Fascia Involvement
GVHD can tighten the fascia (the connective tissue around muscles, organs, and joints). “With tightening of the skin and the fascia tissue, people can lose joint range of motion,” says Dr. Custodio. “That stiffness impairs their ability to move their hands, shoulders, and legs — and that's going to cause mobility issues.” If not addressed, the stiffness can also lead to permanent shortening of muscles or tendons, known as contractures.
Muscle Weakness
The medications you’re taking to treat GVHD may also cause mobility issues. “The first-line treatment of graft-versus-host disease is steroids or corticosteroids,” says Dr. Alousi. “And one of the side effects of steroids, especially when used in high doses, is muscles becoming weakened over time — a condition we call myopathy.”
Nerve Involvement
Nerve involvement can be a symptom with GVHD, which can affect mobility. “We have nerves that run through the skin and connective tissue, so when the skin becomes thickened and hard, that can sometimes result in pain and neuropathy,” says Dr. Alousi.
Issues with nerves may also stem from treatment prior to a transplant. “A lot of patients have undergone various regimens of chemotherapy — and those treatments can cause some of these patients to develop neuropathy,” says Custodio.
3 Ways to Prevent and Improve Mobility Issues
Try these steps to maintain and increase mobility.
1. Physical or Occupational Therapy
To help preserve flexibility and prevent permanent joint stiffness, your care team may prescribe physical therapy, occupational therapy, or both. According to Custodio, whether the impairment is in your "shoulders, hips, hands, or knees" will dictate which therapy you need.
A physical therapist focuses on mobility and safety; for instance, they can help minimize falls, which are a higher risk when skin thickening around the ankles and feet affects your balance, says Alousi.
An occupational therapist focuses on function and joint mobility. At MD Anderson, this may include specialized programs to reverse contractures with a specialized cast that holds the joint and stretches tissues, says Alousi.
Your medications can also play a role. Long-term or high-dose steroid use can weaken muscles, a condition called myopathy, explains Alousi. “Because steroids can cause muscle weakness, we often proactively refer patients on steroids to physical or occupational therapy to maintain strength and prevent significant myopathy,” he says.
2. Daily Gentle Movement
Stretching and range-of-motion exercises can help with mobility, but these movements need to be tailored to your exact needs. “People with GVHD need very special, individualized stretching to treat target areas,” says Alousi. “Stretching is very specific to where the scarring is and geared to where the limitations are.”
3. Medications
Immunosuppressive treatments prescribed by your transplant team can reduce inflammation and slow or prevent tissue damage. “Medicines like tacrolimus and belumosudil address the autoimmune effects of GVHD, and that in turn helps improve mobility or diminish the effects it can have on mobility,” says Custodio. “They can help with softening of the tight skin and loosening of the joints, and that should help improve pain, joint range of motion, and mobility.”
In addition, topical medications such as topical tacrolimus and steroids can further help preserve the integrity of the skin and allow for better range of motion and stretching, says Custodio.
Mobility limitations with GVHD are complex and affect everyone differently, so care needs to be personalized. Take time upfront to talk through your specific symptoms and challenges with your doctor, says Custodio. “Raising any concerns as early as possible to your oncologists or other providers — and getting it assessed and managed early — is going to give you the best chance to preserve and improve your function and mobility,” he says.
The Takeaway
- Mobility issues are common in chronic GVHD due to symptoms such as skin tightening, joint stiffness, and muscle weakness.
- Tailored stretching, physical and occupational therapy, and medications can help prevent or slow down scarring and contractures to maintain and improve mobility.
- Mobility challenges with GVHD aren’t one-size-fits-all, so regular check-ins with your care team are key.
- Yu J et al. Impact of Chronic Graft-versus-Host Disease on Patient Employment, Income, and Informal Caregiver Burden. Transplantation and Cellular Therapy. July 2023.
- Learn Rehabilitation Therapies to Manage Side Effects of Chronic Graft-versus-Host Disease. BMT Infonet. May 5, 2022.
- Mohammed J et al. Is There Any Role for Physical Therapy in Chronic GvHD? Bone Marrow Transplantation. August 2017.

Conor Steuer, MD
Medical Reviewer
Conor E. Steuer, MD, is medical oncologist specializing in the care of aerodigestive cancers, mesothelioma, and thymic malignancies and an assistant professor in the department of hematology and medical oncology at the Emory University School of Medicine in Atlanta. He joined the clinical staff at Emory's Winship Cancer Institute as a practicing physician in July 2015. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group and is a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Dr. Steuer received his medical degree from the New York University School of Medicine in 2009. He completed his postdoctoral training as a fellow in the department of hematology and medical oncology at the Emory University School of Medicine, where he was chief fellow in his final year.
He has been active in research including in clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.
Steuer's work has been published in many leading journals, such as Cancer, the Journal of Thoracic Oncology, and Lung Cancer, and has been presented at multiple international conferences.

Laurel Leicht
Author
Laurel Leicht has been a writer and editor for nearly two decades. A graduate of the College of William and Mary and the master's program at the Missouri School of Journalism, she covers a wide range of health and fitness topics, including breast cancer, various chronic conditions, mental health, and cardiovascular health.